Neoadjuvant docetaxel, vinorelbine and trastuzumab prior to surgery and adjuvant therapy is active in patients with HER-2 breast cancer

By  

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

By Murthy Rashmi K.   Varma Ankur   Mishra Priyankana   Hess Kenneth R.   Young Elliana   Murray James L.   Koenig Kimberly H.   Moulder Stacy L.   Melhem-Bertrandt Amal   Giordano Sharon H.   Booser Daniel   Valero Vicente   Hortobagyi Gabriel N.   Esteva Francisco J.  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

Blackwell Publishing

Access to resources Recommend Favorite

Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

By Essers Brigitte A.B.   Seferina Shanley C.   Tjan-Heijnen Vivianne C.G.   Severens Johan L.   Novák Annoesjka   Pompen Marjolein   Oron Ulrich H.   Joore Manuela A.  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 375-380

Blackwell Publishing

Access to resources Recommend Favorite

Trastuzumab: throwing caution to the wind in breast cancer?

By  

Inpharma, Vol. 1, Iss. 1514, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Trastuzumab: throwing caution to the wind in breast cancer?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite